Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers

Archives of Internal Medicine

Volumn 169, Issue 2, 2009, Pages 179-187

  De Perio, Marie A ^a,c   Tsevat, Joel ^a   Roselle, Gary A ^a,b   Kralovic, Stephen M ^a,b   Eckman, Mark H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Surgery   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TUBERCULIN;

ADULT; ARTICLE; BCG VACCINATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HEALTH CARE PERSONNEL; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; MEDICAL RECORD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING TEST; SKIN TEST; TUBERCULIN TEST;

ANTIGENS, BACTERIAL; COST-BENEFIT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH PERSONNEL; HUMANS; INTERFERON-GAMMA; LEUKOCYTES; MALE; MASS SCREENING; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 58849132849     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.524     Document Type: Article

References (52)

1. Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy of control measures in preventing nosocomial transmission of multidrug- resistant tuberculosis to patients and health care workers. Ann Intern Med. 1995; 122(2):90-95.
2. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1-141.
3. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines forusing the Quan- tiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States, 2005 [published correction appears in MMWR Morb Mortal Wkly Rep. 2005;54(50):1288]. MMWR Morb Mortal Wkly Rep. 2005;54(RR-15):49-55.
4. Pai M, Riley LW, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4(12):761-767.
5. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099-1104.
6. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med. 2004;170(1):59-64.
7. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research [published correction appears in Ann Intern Med. 2007;146(9):688]. Ann Intern Med. 2007;146(5):340-344.
8. Department of Veterans Affairs. Volume II: medical programs & information technology programs: congressional submission, FY 2009. http://www.va.gov/budget/summary/2009/Volume-2-Medical-Programs-and-Information- Technology.pdf.AccessedApril2008.
9. Department of Veterans Affairs. VA Handbook 5019: Occupational Health Services. http://www1.va.gov/Ohrm/Directives-Handbooks/Documents/5019.pdf. AccessedFebruary20,2007.
10. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press Inc; 1996.
11. Lau J, Kassirer JP, Pauker SG. Decision Maker 3.0: improved decision analysis by personal computer. Med Decis Making. 1983;3(1):39-43.
12. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis incidence-United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(11): 245-250.
13. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137(1):215-220.
14. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2004. Atlanta, GA: US Dept of Health and Human Services; September 2005.
15. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004; 169(10):1103-1109.
16. Brock l, Rugwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-γ test. Resp Res. 2006;7(1):e56. http://www. pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmedandpubmedid=16579856. Accessed October 8, 2008.
17. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005;293 (22):2756-2761.
18. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367(9519):1328-1334.
19. Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a commercial whole blood interferon-γ assay for tuberculosis infection. Am J Respir Crit Care Med. 2005;172(5):631-635.
20. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006; 28(1):24-30.
21. Brock I, Munk ME, Kok-Jensen A, Andersen P. Performance of whole blood IFN- gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CPT-10. Int J Tuberc Lung Dis. 2001;5(5):462-467.
22. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical reevalu- ation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis. 2006; 43(12):1540-1546.
23. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-γ release assay for detection of active tuberculosis. Clin Infect Dis. 2007; 44(1):69-73.
24. Pai M, Joshi R, Bandyopadhyay P, et al. Sensitivity of a whole-blood interferon- gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection. 2007;35(2):98-103.
25. Grinsdale J, Kawamura LM. Community-based tuberculosis screening using QuantiFERON-TB Gold: the San Francisco experience. Paper presented at: Rethinking the Epidemiology of Tuberculosis Infection: The First Global Symposium on Interferon-gamma Assays; February 22, 2007; Vancouver, British Columbia, Canada.
26. Ravn P, Munk ME, Andersen AB, et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol. 2005;12(4):491-496.
27. Goletti D, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol. 2005;12(11):1311-1316.
28. Johnson PD, Stuart RL, Grayson ML, et al. Tuberculin-purified protein derivative, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol. 1999;6(6):934-937.
29. Taggart EW, Hill HR, Ruegner RG, Litwin CM. Evaluation of an in vitro assay for interferon gamma production in response to the Mycobacterium tuberculosis- synthesized peptide antigens ESAT-6 and CFP-10 and the PPD skin test. Am J Clin Pathol. 2006;125(3):467-473.
30. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for the diagnosis of tuberculosis. J Clin Microbiol. 2006;44(8):2844-2850.
31. LoBue PA, Catanzaro A. Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital. Chest. 1998;113(5):1184-1189.
32. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis. 1978;117(6):991-1001.
33. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555-564.
34. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 1994; 271(9):698-702.
35. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia: twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 1976;91(3):276-280.
36. Arias E. United States life tables, 2003. Natl Vital Stat Rep. 2006;54(14):1-40.
37. Smith MW, Velez JP. A guide to estimating wages of VHA employees. July 2004. http://wrww.herc.research.va.gov/publications/technical-reports.asp. AccessedMarch1,2007.
38. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk reactors older than 35 years of age: a risk-benefit and cost- effectiveness analysis. Ann Intern Med. 1997;127(12):1051-1061.
39. Centers forMedicare and Medicaid Services. National physician fee schedule relative value file. 2005. htrtp://www.cms.hhs.gov/PhysicianFeeSched/ pfsrvf/list.asp.AccessedFebruary20,2007.
40. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized formultidrug- resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8(8):1012-1016.
41. Bureau of Labor Statistics, US Department of Labor. Consumer Price Index. http://data.bls.gov/cgi-bin/cpicalc.pl.AccessedMarch2007.
42. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007;11(1):16-26.
43. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-γ release assay screening for latent tuberculosis infection treatment in Germany. Chest. 2007;131(5):1424-1434.
44. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate- strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med. 1971;285(27):1506-1509.
45. Battershill JH. Cutaneous testing in the elderly patientwith tuberculosis. Chest. 1980;77(2):188-189.
46. Howard WL, Klopfenstein MD, Steininger WJ, Woodruff CE. The loss of tuberculin sensitivity in certain patients with active pulmonary tuberculosis. Chest. 1970;57(6):530-534.
47. Frenzel EC, Thomas GA, Hanna HA. The importance of two-step tuberculin skin testing for newly employed healthcare workers. Infect Control Hosp Epidemiol. 2006;27(5):512-514.
48. Hallak KM, Schenk M, Neale AV. Evaluation of the two-step tuberculin skin test in health care workers at an inner-city medical center. J Occup Environ Med. 1999; 41(5):393-396.
49. Sepkowitz KA, Feldman J, Louther J, Rivera P, Villa N, DeHovitz J. Benefit of two- step PPD testing of newemployees at a New York City hospital. Am J Infect Control. 1997;25(3):283-286.
50. Swinker M. Prevalence of positive tuberculin skin reactions in a two-step testing program at a tertiary-care center in eastern North Carolina. Infect Control Hosp Epidemiol. 2000;21(1):39-40.
51. Rattner SL, Fleischer JA, Davidson BL. Tuberculin positivity and patient contact in healthcare workers in the urban United States. Infect Control Hosp Epidemiol. 1996;17(6):369-371.
52. Ball R, Van Wey M. Tuberculosis skin test conversion among health care workers ata military medical center. Mil Med. 1997;162(5):338-343.